
|Videos|November 19, 2013
The Role of Chemotherapy in Prostate Cancer
Author(s)William Kevin Kelly, DO
William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.
Advertisement
William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the role of chemotherapy in castration-resistant prostate cancer (CRPC).
Clinical Pearls
- Chemotherapy has been used to treat CRPC for a long time
- Docetaxel has become a key chemotherapy agent used to treat CRPC for the last decade
- Physicians have tried to use docetaxel with other newer targeted agents, but combining agents with docetaxel has not shown any clinical benefit
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































